137
Participants
Start Date
May 18, 2016
Primary Completion Date
February 13, 2019
Study Completion Date
February 13, 2019
INCB057643
Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
Gemcitabine
Standard of Care (SOC) agents
Paclitaxel
Standard of Care (SOC) agents
Rucaparib
Standard of Care (SOC) agents
Abiraterone
Standard of Care (SOC) agents
Ruxolitinib
Standard of Care (SOC) agents
Azacitidine
Standard of Care (SOC) agents
University of Rochester, Wilmot Cancer Center, Rochester
Wake Forest Baptist Health, Winston-Salem
University of North Carolina at Chapel Hill, Chapel Hill
Sylvester Comprehensive Cancer Center, Miami
Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie
University of Michigan, Ann Arbor
University of Minnesota, Minneapolis
Washington University, St Louis
HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris
Oncology Consultants, P.A., Houston
The Methodist Hospital, Houston
Sarah Cannon Research Institute at Health One, Denver
Huntsman Cancer Institute, Salt Lake City
University of California, La Jolla
MultiCare Institute for Research and Innovation, Tacoma
University of Alabama, Birmingham
Yale University, New Haven
Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels
Lead Sponsor
Incyte Corporation
INDUSTRY